Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sarah Blocker
Observed name:
S. Blocker
Institutions:
Barnes-Jewish Hospital,
Nebraska Medical Center,
The University of Kansas Cancer Center
Observed institutions:
Barnes-Jewish Hospital,
Nebraska Medical Center,
The University of Kansas Cancer Center
ORCID:
0000-0002-1007-0112
Observed ORCID:
0000-0002-1007-0112
OpenAlex ID:
A5123763171
Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR Database
2026
·
Diana Kim
, Sarah Blocker
, et al.
·
Clinical Lung Cancer
·
5
Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice
2026
·
Sarah Blocker
, Diana Kim
, et al.
·
European Journal of Cancer
·
4
Evaluation of atezolizumab, durvalumab, lurbinectedin, and tarlatamab in high-grade extrapulmonary neuroendocrine carcinoma: A multicenter retrospective comparative analysis.
2026
·
Ty Michael Moore
, Courtney C. Cavalieri
, et al.
·
Journal of Clinical Oncology
·
2
PDF
Delta-Like Ligand 3 Expression by Immunohistochemistry in Rare Neuroendocrine Neoplasms and Associated Response to Off-Label Tarlatamab Treatment
2026
·
Timothy Schieber
, Jacob Hobbs
, et al.
·
JCO Precision Oncology
·
2
Real-World Outcomes of Abemaciclib Dose-Escalation Strategy in High-Risk Early Breast Cancer
2026
·
Noor Lad
, Sarah Blocker
, et al.
·
Clinical Breast Cancer
·
1
Low Statin Use Post-liver Transplant Despite Increased Rates of Dyslipidemia
2026
·
Sarah Blocker
, Molly Henry
, et al.
·
Journal of Pharmacy Practice
Analysis of corticosteroid exposure on efficacy of tarlatamab in small cell lung cancer: A multicenter retrospective study.
2026
·
Ty Michael Moore
, Courtney C. Cavalieri
, et al.
·
Journal of Clinical Oncology
Corrigendum to “Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice” [Eur. J. Cancer 238 (May) (2026) 116686]
2026
·
Sarah Blocker
, Diana Kim
, et al.
·
European Journal of Cancer
PDF
174P Efficacy outcomes and risk factors for CRS and ICANS with tarlatamab in small cell lung cancer: Insights from clinical practice
2025
·
J. Zhang
, S. Blocker
, et al.
·
Immuno-Oncology Technology
50P DLL3 expression by immunohistochemistry in rare neuroendocrine neoplasms and associated response to off label tarlatamab
2025
·
T. Schieber
, J. Hobbs
, et al.
·
Immuno-Oncology Technology
PDF
Show more works
View as search
Works count:
10
Citation count:
14
H-index:
2
I10-index:
Year
Topic
Type